Technical Analysis for PTX - Pernix Therapeutics Holdings, Inc.

Grade Last Price % Change Price Change
grade F 0.207 -6.76% -0.02
PTX closed down 5.91 percent on Monday, March 4, 2019, on 58 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical PTX trend table...

Date Alert Name Type % Chg
Mar 4 New 52 Week Closing Low Bearish 0.00%
Mar 4 Narrow Range Bar Range Contraction 0.00%
Mar 4 NR7 Range Contraction 0.00%
Mar 4 New 52 Week Low Weakness 0.00%
Mar 4 Wide Bands Range Expansion 0.00%
Mar 4 Down 3 Days in a Row Weakness 0.00%
Mar 4 Oversold Stochastic Weakness 0.00%
Mar 1 New 52 Week Closing Low Bearish -5.91%
Mar 1 Narrow Range Bar Range Contraction -5.91%
Mar 1 New 52 Week Low Weakness -5.91%

Older signals for PTX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Pernix Therapeutics Holdings, Inc. focuses on developing, manufacturing, marketing, and selling branded and generic pharmaceutical products for pediatric and adult indications in various therapeutic areas. Its products include CEDAX, a oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogenes; NATROBA, a prescription medicine used to treat head lice in adults and children; and VERIPRED, a prescription drug product for the control of allergic conditions in adult and pediatric populations with seasonal or perennial allergic rhinitis, asthma, contact and atopic dermatitis, serum sickness, and drug hypersensitivity reactions. The company's products also comprise OMECLAMOX-PAK for the treatment of patients with H.pylori infection and duodenal ulcer disease; REZIRA and ZUTRIPRO, which are oral solutions for the relief of cough and nasal congestion; SILENOR, a prescription medicine used to treat insomnia characterized by difficulty with sleep maintenance; REPREXAIN for the short-term management of acute pain; REZYST, a proprietary probiotic blend to promote the dietary management; and prescription drugs for cough and cold under the BROVEX, ALDEX, and PEDIATEX names. In addition, it offers various generic pharmaceutical products in the areas of nutritional supplements, analgesics, urinary tract, women's health, prenatal vitamins, and dental health, as well as iron deficiency and nephrology. Further, the company, through its joint venture agreement with SEEK, is developing BC 1036, an antitussive cough suppressant pharmaceutical product. Additionally, it is developing a prescription product for the pediatrics market. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. The company was incorporated in 1996 and is headquartered in The Woodlands, Texas.
Manufacturing Pain Drugs Chemical Compounds Medication Health Sciences Asthma Morphinans Atopic Dermatitis Cough Generic Pharmaceutical Products Medical Prescription Prodrugs Heroin Insomnia Pernix Therapeutics Holdings Dietary Management Iron Deficiency Short Term Management
Is PTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.3
52 Week Low 0.203
Average Volume 1,726,018
200-Day Moving Average 1.2301
50-Day Moving Average 0.5192
20-Day Moving Average 0.6722
10-Day Moving Average 0.2984
Average True Range 0.1689
ADX 26.78
+DI 33.5209
-DI 32.4253
Chandelier Exit (Long, 3 ATRs ) 1.6933
Chandelier Exit (Short, 3 ATRs ) 0.7097
Upper Bollinger Band 1.5936
Lower Bollinger Band -0.2492
Percent B (%b) 0.25
BandWidth 274.1446
MACD Line -0.1037
MACD Signal Line -0.0256
MACD Histogram -0.0781
Fundamentals Value
Market Cap 2.3 Million
Num Shares 11.1 Million
EPS -16.97
Price-to-Earnings (P/E) Ratio -0.01
Price-to-Sales 0.23
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.26
Resistance 3 (R3) 0.26 0.25 0.25
Resistance 2 (R2) 0.25 0.24 0.25 0.25
Resistance 1 (R1) 0.23 0.23 0.22 0.22 0.24
Pivot Point 0.22 0.22 0.21 0.21 0.22
Support 1 (S1) 0.19 0.20 0.19 0.19 0.17
Support 2 (S2) 0.18 0.19 0.18 0.17
Support 3 (S3) 0.16 0.18 0.17
Support 4 (S4) 0.16